Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Buy
73
FOLD Quote, Financials, Valuation and Earnings
Last price:
$14.33
Seasonality move
:
-4.88%
Day range:
$14.32 - $14.34
52-week range:
$5.51 - $14.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.33x
P/B ratio:
19.19x
Volume:
3.5M
Avg. volume:
16M
1-year change:
53.1%
Market cap:
$4.4B
Revenue:
$528.3M
EPS (TTM):
-$0.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
$179.8M | $0.16 | 20.08% | 234.42% | $14.83 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$232.2M | $2.01 | 5.9% | 130.85% | $110.38 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$833.7M | $0.79 | 11.94% | 32.5% | $90.04 |
|
CRMD
CorMedix, Inc.
|
$128.3M | $0.80 | 200.36% | 90.44% | $16.86 |
|
EKSO
Ekso Bionics Holdings, Inc.
|
$5M | -- | -1.27% | -- | $9.50 |
|
KRYS
Krystal Biotech, Inc.
|
$106.8M | $1.61 | 35.17% | 42.95% | $273.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
$14.33 | $14.83 | $4.4B | -- | $0.00 | 0% | 7.33x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$84.83 | $110.38 | $1.9B | 52.02x | $0.00 | 0% | 2.07x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$54.59 | $90.04 | $10.5B | 20.45x | $0.00 | 0% | 3.46x |
|
CRMD
CorMedix, Inc.
|
$6.78 | $16.86 | $534.2M | 3.30x | $0.00 | 0% | 2.28x |
|
EKSO
Ekso Bionics Holdings, Inc.
|
$8.86 | $9.50 | $23.1M | -- | $0.00 | 0% | 8.23x |
|
KRYS
Krystal Biotech, Inc.
|
$285.04 | $273.60 | $8.3B | 42.75x | $0.00 | 0% | 22.79x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.736 | 30.7% | 2.40x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.914 | 5.87% | 2.84x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.954 | 0.48% | 1.60x |
|
EKSO
Ekso Bionics Holdings, Inc.
|
33.86% | -1.459 | 36.98% | 0.99x |
|
KRYS
Krystal Biotech, Inc.
|
0.83% | -0.755 | 0.19% | 9.43x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
EKSO
Ekso Bionics Holdings, Inc.
|
$2.5M | -$1.4M | -58.51% | -85.7% | -33.17% | -$2.1M |
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
Amicus Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns FOLD or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 10.59%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About FOLD or ANIP?
Amicus Therapeutics, Inc. has a consensus price target of $14.83, signalling upside risk potential of 3.51%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $110.38 which suggests that it could grow by 30.11%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.2 5 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is FOLD or ANIP More Risky?
Amicus Therapeutics, Inc. has a beta of 0.417, which suggesting that the stock is 58.311% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.46%.
-
Which is a Better Dividend Stock FOLD or ANIP?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FOLD or ANIP?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 52.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.33x versus 2.07x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.33x -- $169.1M $17.3M ANIPANI Pharmaceuticals, Inc.2.07x 52.02x $227.8M $24.1M
-
Which has Higher Returns FOLD or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of -3.91%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About FOLD or BMRN?
Amicus Therapeutics, Inc. has a consensus price target of $14.83, signalling upside risk potential of 3.51%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $90.04 which suggests that it could grow by 64.95%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.2 5 0 BMRNBioMarin Pharmaceutical, Inc.13 7 0 -
Is FOLD or BMRN More Risky?
Amicus Therapeutics, Inc. has a beta of 0.417, which suggesting that the stock is 58.311% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.267, suggesting its less volatile than the S&P 500 by 73.343%.
-
Which is a Better Dividend Stock FOLD or BMRN?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or BMRN?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Amicus Therapeutics, Inc.'s net income of $17.3M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 20.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.33x versus 3.46x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.33x -- $169.1M $17.3M BMRNBioMarin Pharmaceutical, Inc.3.46x 20.45x $786.8M -$30.7M
-
Which has Higher Returns FOLD or CRMD?
CorMedix, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 49.9%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About FOLD or CRMD?
Amicus Therapeutics, Inc. has a consensus price target of $14.83, signalling upside risk potential of 3.51%. On the other hand CorMedix, Inc. has an analysts' consensus of $16.86 which suggests that it could grow by 148.63%. Given that CorMedix, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.2 5 0 CRMDCorMedix, Inc.4 0 0 -
Is FOLD or CRMD More Risky?
Amicus Therapeutics, Inc. has a beta of 0.417, which suggesting that the stock is 58.311% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.
-
Which is a Better Dividend Stock FOLD or CRMD?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or CRMD?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.33x versus 2.28x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.33x -- $169.1M $17.3M CRMDCorMedix, Inc.2.28x 3.30x $104.3M $108.6M
-
Which has Higher Returns FOLD or EKSO?
Ekso Bionics Holdings, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of -33.62%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat Ekso Bionics Holdings, Inc.'s return on equity of -85.7%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M EKSOEkso Bionics Holdings, Inc.60.3% -$0.54 $14.6M -
What do Analysts Say About FOLD or EKSO?
Amicus Therapeutics, Inc. has a consensus price target of $14.83, signalling upside risk potential of 3.51%. On the other hand Ekso Bionics Holdings, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 7.22%. Given that Ekso Bionics Holdings, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Ekso Bionics Holdings, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.2 5 0 EKSOEkso Bionics Holdings, Inc.1 1 0 -
Is FOLD or EKSO More Risky?
Amicus Therapeutics, Inc. has a beta of 0.417, which suggesting that the stock is 58.311% less volatile than S&P 500. In comparison Ekso Bionics Holdings, Inc. has a beta of 0.710, suggesting its less volatile than the S&P 500 by 29.033%.
-
Which is a Better Dividend Stock FOLD or EKSO?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ekso Bionics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. Ekso Bionics Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or EKSO?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are larger than Ekso Bionics Holdings, Inc. quarterly revenues of $4.2M. Amicus Therapeutics, Inc.'s net income of $17.3M is higher than Ekso Bionics Holdings, Inc.'s net income of -$1.4M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while Ekso Bionics Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.33x versus 8.23x for Ekso Bionics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.33x -- $169.1M $17.3M EKSOEkso Bionics Holdings, Inc.8.23x -- $4.2M -$1.4M
-
Which has Higher Returns FOLD or KRYS?
Krystal Biotech, Inc. has a net margin of 10.24% compared to Amicus Therapeutics, Inc.'s net margin of 81.15%. Amicus Therapeutics, Inc.'s return on equity of -7.02% beat Krystal Biotech, Inc.'s return on equity of 19.91%.
Company Gross Margin Earnings Per Share Invested Capital FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B -
What do Analysts Say About FOLD or KRYS?
Amicus Therapeutics, Inc. has a consensus price target of $14.83, signalling upside risk potential of 3.51%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $273.60 which suggests that it could fall by -4.01%. Given that Amicus Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FOLDAmicus Therapeutics, Inc.2 5 0 KRYSKrystal Biotech, Inc.11 0 0 -
Is FOLD or KRYS More Risky?
Amicus Therapeutics, Inc. has a beta of 0.417, which suggesting that the stock is 58.311% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.705%.
-
Which is a Better Dividend Stock FOLD or KRYS?
Amicus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FOLD or KRYS?
Amicus Therapeutics, Inc. quarterly revenues are $169.1M, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. Amicus Therapeutics, Inc.'s net income of $17.3M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Amicus Therapeutics, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 42.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics, Inc. is 7.33x versus 22.79x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FOLDAmicus Therapeutics, Inc.7.33x -- $169.1M $17.3M KRYSKrystal Biotech, Inc.22.79x 42.75x $97.8M $79.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
75
AGX alert for Jan 17
Argan, Inc. [AGX] is up 16.4% over the past day.
Buy
80
ASTS alert for Jan 17
AST Spacemobile, Inc. [ASTS] is up 14.32% over the past day.
Buy
84
IREN alert for Jan 17
IREN Ltd. [IREN] is up 11.35% over the past day.
